Ophthalmic uses of tissue plasminogen activator
SJO-Saudi Journal of Ophthalmology. 1992; 6 (3): 130-4
in English
| IMEMR
| ID: emr-26328
ABSTRACT
Tissue plasminogen activator [tPA] is a protease enzyme which catalyzes the conversion of plasminogen to plasmin. It is synthesized in vivo by human vascular endothelial cells and has also been manufactured in vitro, using recombinant DNA technology. Experimental and clinical investigations have been performed evaluating the efficacy of tPA in the treatment of different ophthalmologic disorders. Use of tPA has proven beneficial in the treatment of selected cases of hyphema, postoperative fibrin formation, and subretinal hemorrhage. Toxicity studies have demonstrated that 25 micro g of intraocular tPA is safe in nonvitrectomized eyes. We present a review of the literature with regard to the use of tPA
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Ophthalmology
/
Hyphema
/
Retinal Hemorrhage
/
Glaucoma
Limits:
Humans
Language:
English
Journal:
Saudi J. Ophthalmol.
Year:
1992
Similar
MEDLINE
...
LILACS
LIS